Given the volatile nature of the markets, investors should pay attention to the latest moves made by elite hedge funds and other investors in their conviction picks, to get a better idea of the companies and sectors that they are confident in and those in which they may be losing faith. With that mind, we have embedded one of the newest 13G filings below and on the following pages, submitted to the SEC by Eastern Capital. The filing reveals a 3.80 million-share position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), accounting for 4.5% of the company’s stock.
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
EASTERN CAPITAL LIMITED | 0 | 3,802,341 | 0 | 3,802,341 | 3,802,341 | 4.5% |
PORTFOLIO SERVICES LTD | 0 | 3,802,341 | 0 | 3,802,341 | 3,802,341 | 4.5% |
KENNETH B. DART | 0 | 3,802,341 | 0 | 3,802,341 | 3,802,341 | 4.5% |
Page 1 of 8 SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange
Act of 1934
(Amendment No. 4)*
Alnylam Pharmaceuticals, Inc.
(Name of Issuer)
COMMON STOCK, $0.01
PAR VALUE PER SHARE
(Title of Class of Securities)
02043Q107
(CUSIP Number)
William Sullivan,
10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 25, 2016
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule
13d-1(b)
☒ Rule
13d-1(c)
¨ Rule 13d-1(d)
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover
page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 2 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 2 | ||
1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) EASTERN CAPITAL LIMITED | |||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ¨ (b) ¨ | |||
3. | SEC USE ONLY | |||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | ||
6. | SHARED VOTING POWER 3,802,341 | |||
7. | SOLE DISPOSITIVE POWER 0 | |||
8. | SHARED DISPOSITIVE POWER 3,802,341 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,802,341 | |||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨ | |||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.5% | |||
12. | TYPE OF REPORTING PERSON (see instructions) CO | |||
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 3 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 3 | ||
1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) PORTFOLIO SERVICES LTD. | |||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ¨ (b) ¨ | |||
3. | SEC USE ONLY | |||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | ||
6. | SHARED VOTING POWER 3,802,341 | |||
7. | SOLE DISPOSITIVE POWER 0 | |||
8. | SHARED DISPOSITIVE POWER 3,802,341 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,802,341 | |||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨ | |||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.5% | |||
12. | TYPE OF REPORTING PERSON (see instructions) CO | |||
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 4 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 4 | ||
1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) KENNETH B. DART | |||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ¨ (b) ¨ | |||
3. | SEC USE ONLY | |||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | ||
6. | SHARED VOTING POWER 3,802,341 | |||
7. | SOLE DISPOSITIVE POWER 0 | |||
8. | SHARED DISPOSITIVE POWER 3,802,341 |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,802,341 | |||
10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨ | |||
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.5% | |||
12. | TYPE OF REPORTING PERSON (see instructions) IN | |||
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 5 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 5 | ||
Item 1.
(a) | Name of Issuer Alnylam Pharmaceuticals, Inc. | |
(b) | Address of Issuer’s Principal Executive Offices 300 Third Street, Cambridge MA 02142 | |
Item 2.
(a) | Name of Person Filing Eastern Capital Limited is a direct wholly owned subsidiary of Portfolio 2) PORTFOLIO SERVICES LTD. Portfolio Services Ltd. is a holding company which owns all of the outstanding 3) KENNETH B. DART Mr. Dart is the beneficial owner of all of the outstanding shares of Portfolio | |
(b) | Address of the Principal Office or, if none, residence Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS 2) 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS 3) P.O. Box 31300 Grand Cayman, KY1-1206 CAYMAN ISLANDS | |
(c) | Citizenship
2) CAYMAN ISLANDS 3) BRITISH OVERSEAS TERRITORY CITIZEN CAYMAN ISLANDS | |
(d) | Title of Class of Securities Common Stock, USD$0.01 par value per share | |
(e) | CUSIP Number 02043Q107 | |
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 6 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 6 | ||
Item 3. If this statement is filed pursuant
to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a) | ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). | |
(b) | ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). | |
(c) | ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). | |
(d) | ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
(e) | ¨ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); | |
(f) | ¨ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); | |
(g) | ¨ | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); | |
(h) | ¨ | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); | |
(i) | ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); | |
(j) | ¨ | Group, in accordance with §240.13d-1(b)(1)(ii)(J). | |
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
The percentage ownership noted in this Schedule 13G/A is based on 85,138,602
shares outstanding as of January 29, 2016 as reported in the Issuer 10-Q filed with the U.S. Securities Exchange and Commission
on February 12, 2016.
As of the date of this filing, Eastern Capital Limited, Portfolio Services
Ltd. and Mr. Dart beneficially own in aggregate the following:
(a) | Amount beneficially owned: 3,802,341 | ||||
(b) | Percent of class: 4.5% | ||||
(c) | Number of shares as to which the person has: | ||||
(i) | Sole power to vote or to direct the vote 0 | ||||
(ii) | Shared power to vote or to direct the vote 3,802,341 | ||||
(iii) | Sole power to dispose or to direct the disposition of 0 | ||||
(iv) | Shared power to dispose or to direct the disposition of 3,802,341 | ||||
Instruction. For computations regarding securities
which represent a right to acquire an underlying security see §240.13d-3(d)(1).
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 7 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 7 | ||
Item 5. Ownership of Five Percent or
Less of a Class.
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following ☒.
Instruction. Dissolution of a group requires
a response to this item.
Item 6. Ownership of More than Five Percent
on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not Applicable
Item 8. Identification and Classification
of Members of the Group.
Not Applicable
Item 9. Notice of Dissolution of Group.
Not Applicable
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. |
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Page 8 of 8 SEC Filing
CUSIP No. 02043Q107 | 13G/A | Page 8 | ||
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Eastern Capital Limited |
03/01/2016 Date |
/s/ Signature |
Kenneth Name/Title |
Portfolio Services Ltd. |
03/01/2016 |
Date |
/s/ Signature |
Kenneth Name/Title |
Kenneth B. Dart |
03/01/2016 |
Date |
/s/ Signature |
Kenneth Name/Title |